Review article · 2023 · Open access
Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials
BMJ Open, 13(2), e064504 · Published 1 February 2023 · DOI 10.1136/bmjopen-2022-064504
In brief
“Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials” is a 2023 review article by Spyridon Siafis and 8 co-authors, published in BMJ Open. OpenAlex counts 2 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at BMJ Open.
- Citations
- 2
- Most cited in
- 2024 (1)
- Field-weighted impact
- 0.06
- References
- 35
- Authors
- 9
Abstract
INTRODUCTION: Guidelines recommend clozapine for treatment-resistant schizophrenia. However, meta-analysis of aggregate data (AD) did not demonstrate higher efficacy of clozapine compared with other second-generation antipsychotics but found substantial heterogeneity between trials and variation between participants in treatment effects. Therefore, we will conduct an individual participant data (IPD) meta-analysis to estimate the efficacy of clozapine compared with other second-generation antipsychotics while accounting for potentially important effect modifiers. METHODS AND ANALYSIS: In a systematic review, two reviewers will independently search Cochrane Schizophrenia Group's trial register (without restrictions in date, language or state of publication) and related reviews. We will include randomised controlled trials (RCTs) in participants with treatment-resistant schizophrenia comparing clozapine with other second-generation antipsychotics for at least 6 weeks. We will apply no restrictions in age, gender, origin, ethnicity or setting, but exclude open-label studies, studies from China, experimental studies and phase II of cross-over trials. IPD will be requested from trial authors and cross-check against published results. AD will be extracted in duplicate. Risk of bias will be assessed using Cochrane's Risk of Bias 2 tool.The primary outcome will be overall symptoms of schizophrenia.We will synthesise results using random-effects meta-analysis and meta-regression methods in a 3-level Bayesian model. The model combines IPD with AD when IPD is not available for all studies, and include participant, intervention and study design characteristics as potential effect modifiers. The effect size measures will be mean difference (or standardised mean difference when different scales were used). Confidence in the evidence will be assessed using GRADE. ETHICS AND DISSEMINATION: This project has been approved by the ethics commission of the Technical University of Munich (#612/21 S-NP). The results will be published open-access in a peer-review journal and a plain-language version of the results will be disseminated.If we need to amend this protocol, we will describe the change and give the rationale in a specific section in the resulting publication 'Changes with respect to the protocol'. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (#CRD42021254986).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Siafis, S., Schneider‐Thoma, J., Hamza, T., Bighelli, I., Dong, S., Hansen, W., Davis, J. M., Salanti, G., & Leucht, S. (2023). Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open, 13(2), e064504. https://doi.org/10.1136/bmjopen-2022-064504
MLA 9
Siafis, Spyridon, et al. “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.” BMJ Open, vol. 13, no. 2, 2023, p. e064504. https://doi.org/10.1136/bmjopen-2022-064504.
Chicago
Siafis, Spyridon, Johannes Schneider‐Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, and Stefan Leucht. 2023. “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.” BMJ Open 13 (2): e064504. https://doi.org/10.1136/bmjopen-2022-064504.
Harvard
Siafis, S. et al. (2023) ‘Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials’, BMJ Open, 13(2), p. e064504. doi:10.1136/bmjopen-2022-064504.
IEEE
S. Siafis et al., “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials,” BMJ Open, vol. 13, no. 2, p. e064504, 2023, doi: 10.1136/bmjopen-2022-064504.
BibTeX
@article{siafis2023efficacy,
title = {{Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials}},
author = {Siafis, Spyridon and Schneider‐Thoma, Johannes and Hamza, Tasnim and Bighelli, Irene and Dong, Shimeng and Hansen, Wulf‐Peter and Davis, John M. and Salanti, Georgia and Leucht, Stefan},
journal = {BMJ Open},
year = {2023},
volume = {13},
number = {2},
pages = {e064504},
doi = {10.1136/bmjopen-2022-064504},
url = {https://doi.org/10.1136/bmjopen-2022-064504}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- clozapine
- atypical antipsychotics
- treatment-resistant schizophrenia
- antipsychotic efficacy
- individual patient data meta-analysis
- effect modifiers
- symptom outcomes
- Bayesian hierarchical model
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Siafis, S., Schneider‐Thoma, J., Hamza, T., Bighelli, I., Dong, S., Hansen, W., Davis, J. M., Salanti, G., & Leucht, S. (2023). Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open, 13(2), e064504. https://doi.org/10.1136/bmjopen-2022-064504
How many times has this paper been cited?
2 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at BMJ Open: sign in and open the PDF from this page.
Who wrote this paper?
Spyridon Siafis, Johannes Schneider‐Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, Stefan Leucht.
What is the DOI of this paper?
10.1136/bmjopen-2022-064504, permanently at https://doi.org/10.1136/bmjopen-2022-064504. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.